387 related articles for article (PubMed ID: 14723254)
21. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
Glauser MP; Brennscheidt U; Cornely O; Grigg A; Figuera A; Keyserling C; Trostmann U; Welling L; Tack K
Clin Microbiol Infect; 2002 Jan; 8(1):14-25. PubMed ID: 11906496
[TBL] [Abstract][Full Text] [Related]
22. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
[TBL] [Abstract][Full Text] [Related]
23. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.
Aparicio J; Oltra A; Llorca C; Montalar J; Herranz C; Gómez-Codina J; Pastor M; Munárriz B
Eur J Cancer; 1996 Sep; 32A(10):1739-43. PubMed ID: 8983283
[TBL] [Abstract][Full Text] [Related]
24. Meropenem monotherapy as an empirical treatment of febrile neutropenia in childhood cancer patients.
Erbey F; Bayram I; Yilmaz S; Tanyeli A
Asian Pac J Cancer Prev; 2010; 11(1):123-6. PubMed ID: 20593941
[TBL] [Abstract][Full Text] [Related]
25. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.
Erman M; Akova M; Akan H; Korten V; Ferhanoğlu B; Köksal I; Cetinkaya Y; Uzun O; Unal S;
Scand J Infect Dis; 2001; 33(11):827-31. PubMed ID: 11760163
[TBL] [Abstract][Full Text] [Related]
26. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
[TBL] [Abstract][Full Text] [Related]
27. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
Charnas R; Lüthi AR; Ruch W
Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
[TBL] [Abstract][Full Text] [Related]
28. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure.
Miranda-Novales MG; Belmont-Martinez L; Villasis-Keever MA; Penagos-Paniagua M; Bernaldez-Rios R; Solorzano-Santos F
Arch Med Res; 1998; 29(4):331-5. PubMed ID: 9887552
[TBL] [Abstract][Full Text] [Related]
29. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia.
Malik I; Shaharyar
J Pak Med Assoc; 2002 Jan; 52(1):15-8. PubMed ID: 11963577
[TBL] [Abstract][Full Text] [Related]
30. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Rizal AM; Nordiah AJ; Jamal R
Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
[TBL] [Abstract][Full Text] [Related]
31. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients.
Kobayashi R; Sato T; Nakajima M; Kaneda M; Iguchi A
J Pediatr Hematol Oncol; 2009 Apr; 31(4):270-3. PubMed ID: 19346879
[TBL] [Abstract][Full Text] [Related]
32. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
[TBL] [Abstract][Full Text] [Related]
33. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
34. Meropenem in the treatment of febrile neutropenic children.
Müller J; Garami M; Constantin T; Schmidt M; Fekete G; Kovács G
Pediatr Hematol Oncol; 2005 Jun; 22(4):277-84. PubMed ID: 16020114
[TBL] [Abstract][Full Text] [Related]
35. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of meropenem as an empirical treatment for febrile neutropenia in children with cancer.
Pancharoen C; Mekmullica J; Buranachonapa J; Trongjit D; Nuchprayoon I; Vanichsetakul P; Seksarn P; Thisyakorn U
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S174-8. PubMed ID: 12929986
[TBL] [Abstract][Full Text] [Related]
37. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
[TBL] [Abstract][Full Text] [Related]
38. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime.
Lindblad R; Rödjer S; Adriansson M; Andreasson B; Bäckström B; Johansson P; Karlsson K; Rhedin C; Turesson I
Scand J Infect Dis; 1998; 30(3):237-43. PubMed ID: 9790130
[TBL] [Abstract][Full Text] [Related]
39. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
Sato T; Kobayashi R; Yasuda K; Kaneda M; Iguchi A; Kobayashi K
Pediatr Blood Cancer; 2008 Dec; 51(6):774-7. PubMed ID: 18661495
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia.
Santhosh-Kumar CR; Ajarim DS; Harakati MS; al Momen AK; al Mohareb F; Zeitany RG
J Infect; 1992 Jul; 25(1):11-9. PubMed ID: 1365011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
